Company Overview
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Why Investors Should Care
Net profit has compounded at 32.1% per year over the last five years.
Revenue has grown at a 22.1% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $427.54M (+40.0% YoY); net profit $-21.02M.
- Trailing 12 Months Year-on-year growth — revenue +17.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 22.1%, profit CAGR 32.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 22.13% |
| 1 Year: | 17.40% |
Compounded Profit Growth
| 5 Years: | 32.06% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -24.23% |
| 6 Months: | -53.89% |
| 3 Months: | +2.38% |
| 1 Month: | +2.36% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)49.73 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 22.1% over 5 years.
- Profit CAGR of 32.1% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 62.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | WGS GeneDx Holdings Corp. R2K | 62.43 | -23.47 | $1.85B | 0.00% | -3.15% | -30.42% | 22.13% | 32.06% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.66M | 30.10M | 38.61M | 63.96M | 64.20M | 47.02M | 43.18M | 57.80M | 53.94M | 36.17M | 83.23M | 43.14M | 48.71M | 53.30M | 62.42M | 70.51M | 76.87M | - | 87.11M | 102.69M | 116.74M | 120.99M | 102.25M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.64M | 31.79M | 32.22M | 36.72M | 34.04M |
| Gross Profit | 9.52M | -4.40M | 4.59M | -5.67M | -4.32M | -1.16M | -8.31M | -2.81M | 5.62M | -29.60M | 13.55M | 15.24M | 18.76M | 25.26M | 37.41M | 42.95M | 47.83M | - | 58.48M | 70.90M | 84.53M | 84.27M | 68.21M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 63.03M | 61.94M | 87.78M | 98.50M | 94.39M |
| Operating Income | -26.77M | -34.16M | -56.02M | -125.05M | -196.66M | -45.45M | -88.26M | -115.78M | -89.31M | -162.65M | -90.82M | -60.36M | -51.62M | -42.97M | -13.66M | -10.58M | -7.78M | - | -4.55M | 8.96M | -3.25M | -14.23M | -26.18M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 236.00K | 17.57M | 3.22M | -7.35M | -54.89M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 640.00K | 817.00K | - | - | 717.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.08M | 10.56M | -7.39M | -18.23M | -62.42M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 447.00K | -246.00K | 247.00K | -564.00K | 897.00K |
| Net Income | -26.99M | -32.05M | -56.62M | -125.68M | -191.78M | -46.16M | 32.73M | -40.19M | -76.90M | -85.74M | -77.58M | -60.99M | -46.72M | -42.29M | -20.24M | -29.17M | -8.31M | - | -6.53M | 10.81M | -7.63M | -17.67M | -63.32M |
| Diluted EPS | - | - | -456,573.00 | - | -348.82 | -41.94 | 0.16 | - | -10.38 | -8.38 | -6.72 | -3.04 | -1.84 | -1.64 | -0.78 | -1.10 | -0.31 | - | -0.23 | 0.36 | -0.27 | - | -2.16 |
| R&D Expense | 13.10M | 9.36M | 19.08M | 31.16M | 53.13M | 11.95M | 17.83M | 22.25M | 21.32M | 27.17M | 13.35M | 14.59M | 17.14M | 14.29M | 11.57M | 10.90M | 11.66M | - | 12.58M | 15.08M | 19.83M | - | 19.80M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 196.17M | 179.32M | - | 234.69M | 202.57M | 305.45M | 427.54M |
| Cost of Revenue | - | - | - | 261.44M | 112.56M | 111.05M | 129.37M |
| Gross Profit | 82.78M | 4.03M | - | -26.75M | 90.01M | 194.40M | 298.17M |
| Operating Expenses | - | - | - | 430.76M | 260.20M | 217.61M | 311.25M |
| Operating Income | -30.41M | -241.99M | - | -457.51M | -170.19M | -23.21M | -13.08M |
| EBITDA | - | - | - | -398.20M | -136.46M | -1.26M | 12.15M |
| Interest Expense | - | - | 2.83M | 3.21M | - | - | - |
| Pretax Income | - | - | - | -598.03M | -176.69M | -52.63M | -21.14M |
| Tax Provision | - | - | - | -49.05M | -926.00K | -343.00K | -116.00K |
| Net Income | -29.70M | -241.34M | - | -548.98M | -175.77M | -52.29M | -21.02M |
| Diluted EPS | -264,056.00 | -47,036.00 | - | -53.79 | -7.23 | -1.94 | -0.73 |
| R&D Expense | 34.91M | 72.70M | 105.16M | 86.20M | 58.27M | 45.72M | 72.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 251.64M | 219.30M | 175.53M | 603.36M | - | 490.94M | 418.76M | 419.38M | 523.71M |
| Current Assets | - | - | - | - | - | - | - | 212.62M | 182.34M | 197.97M | 268.29M |
| Cash & Equivalents | - | - | 108.13M | 58.65M | 26.50M | 461.28M | - | 123.93M | 99.68M | 85.21M | 105.00M |
| Inventory | - | - | - | - | - | - | - | 13.66M | 8.78M | 10.65M | 13.95M |
| Receivables | - | - | - | - | - | - | - | 42.63M | 32.37M | 37.63M | 74.37M |
| Total Liabilities | - | - | 247.25M | 406.68M | 407.60M | 212.34M | - | 237.24M | 190.74M | 174.13M | 215.53M |
| Current Liabilities | - | - | 73.44M | 68.70M | 72.61M | 71.61M | - | 144.30M | 58.82M | 54.82M | 108.91M |
| Long Term Debt | - | - | 18.97M | 18.50M | 18.03M | 11.00M | - | 6.25M | 52.69M | 51.91M | 48.18M |
| Total Debt | - | - | - | - | - | - | - | 77.13M | 119.27M | 117.38M | 113.17M |
| Total Equity | -55.97M | -88.71M | -330.05M | -521.83M | -566.50M | 391.02M | - | 253.71M | 228.02M | 245.25M | 308.18M |
| Shares Outstanding | - | - | - | - | - | - | - | 11.77M | 25.98M | 28.02M | 29.25M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.73M | -93.13M | - | -319.15M | -180.15M | -28.50M | 33.28M |
| Investing Cash Flow | -15.46M | -31.97M | - | -141.33M | -43.73M | -30.13M | -61.52M |
| Financing Cash Flow | 148.01M | 129.06M | - | 197.31M | 186.24M | 44.16M | 48.02M |
| Capital Expenditure | -11.92M | -24.09M | - | -14.32M | -5.71M | -5.49M | -19.02M |
| Free Cash Flow | -30.65M | -117.22M | - | -333.48M | -185.86M | -33.99M | 14.26M |
| Net Change in Cash | - | - | - | -263.17M | -37.63M | -14.47M | 19.79M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 42.2% | 2.2% | - | -11.4% | 44.4% | 63.6% | 69.7% |
| Operating Margin % | -15.5% | -134.9% | - | -194.9% | -84.0% | -7.6% | -3.1% |
| Net Margin % | -15.1% | -134.6% | - | -233.9% | -86.8% | -17.1% | -4.9% |
| ROE % | 33.5% | 73.1% | - | -216.4% | -77.1% | -21.3% | -6.8% |
| ROCE % | - | -135.8% | - | -132.0% | -47.3% | -6.4% | -3.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Corvex Management LP | 10.87% | 3.23M | $220.97M |
| 2 | Casdin Capital, LLC | 10.13% | 3.01M | $205.84M |
| 3 | Blackrock Inc. | 5.22% | 1.55M | $106.15M |
| 4 | Westfield Capital Management Co LP | 4.61% | 1.37M | $93.72M |
| 5 | Goldman Sachs Group Inc | 4.50% | 1.33M | $91.38M |
| 6 | ARK Investment Management, LLC | 4.46% | 1.32M | $90.67M |
| 7 | Oracle Investment Management Inc | 2.98% | 884.65K | $60.55M |
| 8 | Vanguard Capital Management LLC | 2.89% | 858.58K | $58.77M |
| 9 | William Blair Investment Management, LLC | 2.61% | 775.27K | $53.07M |
| 10 | Zweig-Dimenna Associates LLC | 2.32% | 689.29K | $47.18M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for WGS
WGS Stock Slumps After Hours As Firm Predicts Lower Test Volume For Year - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQdVVRY0tMQmp4LVdPQWZYQTZzZHZRWEpLUzZKdlFxNXhuWVBIakVyeE8tQmVDNk1aeE9ENnVCakFVVE9XaHVUYVJsM3pfWTVGY1AtY09HY2dKOVk1SUNmdFBndEkwNkprakNFYVJBMFI1SmxmeUZraC1sdDlUR0xkT2JOQzFKSnhISzRkTF…
WGS Jul 2026 63.000 put (WGS260717P00063000) Interactive Stock Chart - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiaEFVX3lxTE45XzVtYkNKTkNSSTQ5dDlWaDUtUnRySUxKblYwekF5dXRaUzQ2TEZJcTlCSHRZR045b3Brb3JCb25RTmJncDNWSzRVbnpaYy14UF9Ic0M2MkFQZ3BWMWJaT2lSZjhOSF8y?oc=5" target="_blank">WGS Jul 2026 63.000 put (WG…
GeneDx Holdings Securities Fraud Class Action Result of - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi7wJBVV95cUxOci1qSXhhYVgycldhazVIQmU0UklISEVOeUJYWU1WRXRvQmNfdmFlWHhObkU5OW11bkhUVFdPYzY2TTFHeHZFTml2T2NRRzl6bi1EZFFaV09iTkp2U3VFT2lCZV9xVi0tOXI2a0xzeTdpSGlWbG5hdjVMYXNLY0NDUElab0RkRGstRGk1bW…
WGS DEADLINE: The Gross Law Firm Reminds GeneDx Holdings Corp. Investors of Upcoming Securities Class Action Deadline - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxPT3duMVBBOW9Ub2NzN19TSDR5SDM1eW1rWW9BSzFaSVhnckZYYjVCNm1VTFhCM1hBcmJBcl9rTk5SalVwaEtTN0MzME9KbjBsaFFLUkRZSWpNWW1aaVozZXNJc0EtWkZiNDdJOFRFOXlnbjR6YUVvbjhVSks2VjNFWFNWSmFmS1JjN0djTm…
WGS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in GeneDx Holdings Corp. Securities Lawsuit - Contact Levi & Korsinsky - Business Wire
<a href="https://news.google.com/rss/articles/CBMiqwJBVV95cUxQQ1NiTFhQVDNJbkJ1ZW45Z2dWbU5ubHZtbjZTOUszbWM0MHROU3BrOW9mYjNTVUhubE81NVR3eEkzVUpHUkVmR09Eclp3ZDdTQjF6YzB5c1UzelZwdGN1NE5yY2xrbkpfOFRJbTFxSW9rQ2l4RWRJQmxyRFBwSzBfa2dOWGhEU0hUVFpfYz…
How Investors Are Reacting To GeneDx Holdings (WGS) Class Actions Over Fabric Impairment And Guidance Cut - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxPb2xob2tYRWFwd2w0a3hPak5EQnNyYUl4NGxVbmhNMW1XWlFGcDFNRFFqZGFsUUJlaEdPOWdRQ0ZSVnE5M1paSFR0R01tcVhkWDc4bXFTcF9XSHhWNWE5SV9rRGdNNzBscTlnOWRqRkZ4UHJMWVNnN1ZZUFlfOFRvODNuNjJRVHoxMTRVdj…
WGS — Frequently Asked Questions
What is the current share price of GeneDx Holdings Corp. (WGS)?
As of 2026-07-14 21:23 PDT, GeneDx Holdings Corp. (WGS) trades at $62.43 on NasdaqGS. Its 52-week range is $34.51 to $167.52.
What is the market capitalisation of WGS?
GeneDx Holdings Corp. (WGS) has a market capitalisation of $1.85B on NasdaqGS.
What is the P/E ratio of WGS?
WGS trades at a trailing price-to-earnings (P/E) ratio of -23.47. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 6.50.
What is the return on equity (ROE) of WGS?
WGS has a return on equity (ROE) of -30.42%. Its return on capital employed (ROCE) is -3.15%.
Is WGS a good stock to buy?
This page provides a data-driven analysis of GeneDx Holdings Corp. (WGS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.